Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant administration of REPEVAX with first dose of GARDASIL and comparison of GARDASIL manufacturing facilities in adolescents
2006-000764-85Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of qHPV vaccine in human papillomavirus infection (3 arms), sponsored by Merck & Co. Primary endpoint: Primary immunogenicity endpoints for antibody response to HPV types 6, 11, 16, and 18. Started Mar 2006; status: completed.
02
Drugs
qHPV vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2006-000764-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000764-85.